A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU

Prior treatment

• Patients with any other diseases that the investigator determines will affect the study results or may weaken the compliance to protocol, including but not limited to:
  • Prior or current autoimmune thyroid disease, but patients with oral thyroxine replacement therapy could be enrolled;
  • Other documented autoimmune diseases (such as hepatitis, immune thrombocytopenia \[ITP\], scleroderma, psoriasis or any autoimmune arthritis);
  • Clinically significant pulmonary infiltration, infectious pneumonia and non-infectious pneumonia, or a past history of interstitial pneumonia at screening;
  • Active infection with systemic manifestations (e.g., presence of bacteria, fungi and human immunodeficiency virus \[HIV\], excluding hepatitis B \[HBV\] and/or hepatitis C \[HCV\] at screening);
  • With evidence of severe retinopathy (e.g., cytomegalovirus \[CMV\]-induced retinitis, macular degeneration) or clinically significant eye diseases (due to diabetes or hypertension);
  • With clinically significant depression or a history of depression;
  • Previously had suicidal attempts or has any risk for suicidal tendency at screening.
• Use any investigational drugs or investigational drug combinations within 4 weeks before the first dose of the study drug, or have not yet recovered from the effects caused by any previously administered investigational drug.
  • Unless with contraindications, acetylsalicylic acid will be considered as background treatment of this study. The following are contraindications to low-dose acetylsalicylic acid: history of allergies to Bayaspirin or any preparations of salicylic acid, peptic ulcer, bleeding tendency, aspirin-induced asthma (asthma attack caused by non-steroidal anti-inflammatory drugs, etc.) and its history. If any contraindications are found, other prophylactic anti-thrombotic drugs can be used.

Other illness

• Any contraindications to interferon α or hypersensitivity to interferon α;
• With severe or serious diseases that the investigator determines may affect the patient's participation in this study;
• History of major organ transplantation;
• Poorly controlled diabetes;
• Thromboembolic complications caused by PV and active abdomina hemorrhage;
• History of any malignancy tumors (except stage 0 chronic lymphocytic leukemia \[CLL\], cured basal cell carcinoma, squamous cell carcinoma and superficial melanoma) in the past 5 years;
• History of alcohol or drug abuse in the past year;

Other

• Patients with symptomatic splenomegaly;
• Pregnant or breastfeeding women;
• History or evidence of post polycythemia vera-myelofibrosis (PPV-MF), essential thrombocythemia, or any non-PV MPN;
• Presence of blast cells in the peripheral blood in the past 3 months;

• Male or female patients aged ≥18 years at the time of signing the informed consent form;
• Patients diagnosed with PV according to the 2016 World Health Organization (WHO) criteria;
• According to the 2020 Guidelines of Chinese Society of Clinical Oncology (CSCO) on Diagnosis and Treatment of Hematological Malignancies, PV patients who are HU resistant or intolerant must meet at least one of the following criteria;
  • Drug resistance: 3 months of treatment at HU doses above 2 g/d
  • Phlebotomy is still required to maintain Hct \<45%;
  • Failure to control the bone marrow proliferation (such as platelet count \>400x10\^9/L and white blood cell count \>10x10\^9/L);
  • spleen shrinkage of less than \>50%;
  • Intolerance
  • At the minimum dose of HU required to achieve complete or partial clinical hematologic response, the absolute neutrophil count (ANC) \<1x10\^9/L or PLT \<100x10\^9/L or HGB \<100 g/L;
  • At any dose of HU treatment, the patient develops lower limb ulcers or other intolerable non-hematologic toxicity, such as skin mucosal manifestations (dark skin, teeth or nails; oral ulcers, mucositis; skin ulcers, rash, and other symptoms), gastrointestinal complaints (nausea, loss of appetite, indigestion, vomiting, abdominal pain, constipation, and other symptoms), pneumonia, fever, etc.
• Have not received interferon therapy previously; or have negative anti-P1101 binding antibody at screening, and the washout time between the last dose of interferon and the first dose of the study drug should not be shorter than 14 days;
• With good liver function at screening, which is defined as total bilirubin ≤1.5 × upper limit of normal (ULN), international normalized ratio (INR) ≤1.5 × ULN, albumin \>3.5 g/dL, alanine aminotransferase (ALT) ≤2.0 × ULN, and aspartate aminotransferase (AST) ≤2.0 × ULN;
• Hemoglobin (HGB) ≥10 g/dL for females, and hemoglobin (HGB) ≥11 g/dL for males at screening;
• Neutrophil count ≥1.5x10\^9/L at screening;
• Creatinine clearance rate ≥40 mL/min at screening (according to the Cockcroft-Gault formula);
• Males and females of childbearing potential, as well as all the females with a menopause duration of less than 2 years, must consent to use acceptable contraceptive methods within 28 days after the last dose of the study drug;
• The patient or the patient's guardian signs the written informed consent, and the patient is able to comply with the study requirements.